Table 12:
Utility Parameters
| Parameter | Utility/Disutility Value | Distribution | Source |
|---|---|---|---|
| Baseline utility of patients with planned fluoropyrimidine treatment | 0.744 | Betaa | Calculatedb |
| Colorectal cancer | 0.756 | — | Bennett et al, 201189 |
| Breast cancer | 0.715 | — | Lloyd et al, 200690 |
| Gastric cancer | 0.710c | — | Curran et al, 200991 |
| Average disutility associated with a severe toxicity | –0.131 | Betaa | Calculated |
| Gastrointestinal | –0.127d | — | Lloyd et al, 200690 |
| Hand-foot syndrome | –0.116 | — | Lloyd et al, 200690 |
| Hematological | –0.150e | — | Lloyd et al, 200690 |
a
Assumed standard error to be 20% of mean.
b
Weighted average of colorectal (55.6%), breast (30.5%), and gastric cancer (13.9%) utilities.
c
Average utility of gastric cancer patients receiving irinotecan, folinic acid with 5-fluourouracil (0.76), and cisplatin with 5-fluourouracil (0.66).
d
Average disutility of diarrhea and vomiting (−;0.103) and stomatitis (−;0.151).
e
Disutility of febrile neutropenia.